Canada’s new drug and biosimilar patent linkage system will fundamentally change the nature of proceedings. J Bradley White and Nathaniel Lipkus of Osler Hoskin & Harcourt discuss key changes of interest to life sciences companies
Michael Loney and Natalie Rahhal analyse five IP decisions issued in Canada, two from the Supreme Court and three from the Federal Court
The landscape for IP litigation has improved considerably in Canada. Kevin P Siu and Steven B Garland of Smart & Biggar
outline the benefits for global rights owners
Federal Circuit’s Brunetti ruling: barring immoral or scandalous marks is unconstitutional restriction of free spee… https://t.co/MivCKFINHg
Federal Circuit rules in Amgen v Sandoz on remand from SCOTUS https://t.co/uYIkfVhCHG https://t.co/2OZAscsz32
RT @mdloney: Canada moves closer to joining the Hague Agreement with the release of proposed new Industrial Design Regulations https://t.co…
End of Year 2017
Tribal sovereign immunity: Taking a wrecking ball to the IPR system
The lawyer behind Allergan’s controversial transfer of patents to a Native American tribe says others are “lining up to do deals”. But, Michael Loney asks, will the PTAB rule that sovereign immunity applies in these types of deals?
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2017 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International